<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423526</url>
  </required_header>
  <id_info>
    <org_study_id>DWP10292</org_study_id>
    <nct_id>NCT01423526</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of DWP10292 in Healthy Male Subjects</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo Controlled, Single-dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of DWP10292 After Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and
      pharmacodynamics of orally administrated DWP10292 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>0 (predose), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24 (2d 0h), 36, 48 (3d 0h), 60, 72 (4d 0h), 96 h(5d 0h) and Post study visit 216h (10d 0h)</time_frame>
    <description>Cmax, AUClast, AUCinf, Tmax, t1/2, CL/F</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety&amp;tolerability</measure>
    <time_frame>0 (predose), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24 (2d 0h), 36, 48 (3d 0h), 60, 72 (4d 0h), 96 h(5d 0h) Post study visit 216h (10d 0h)</time_frame>
    <description>Adverse events, Physical exam, Vital sign, laboratory(CBC,chemistry,U/A etc)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo tablets, oral administration, single administrations
Arms: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP10292</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DWP10292 tablets, oral administration, single administrations
Arms: DWP10292</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP10292</intervention_name>
    <description>Drug: DWP10292 tablets, oral administration, single administration</description>
    <arm_group_label>DWP10292</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, oral administration, single administrations</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

          -  Healthy adult male subjects aged 20 to 45 years

          -  The subject has a Body weight ≥ 60 kg and &lt; 90 kg and Body Mass Index (BMI) ≥ 18.5
             kg/m2 and &lt; 27.0 kg/m2

          -  A Subject who was judged to be healthy by the investigator to participate in this
             study based on screening results (according to standard reference index updated
             recently)

        Exclusion Criteria:

          -  A subject with sign or symptoms or previously diagnosed disease of liver (viral
             hepatitis), digestive system, cardiovascular, kidney, respiratory, endocrinology,
             neurology, immune system, hematology, and psychology function or other significant
             diseases and history or suspicion of current drug abuse and alcohol abuse

          -  A subject who shows vital signs with the number of systolic blood pressure of ≥140
             mmHg or ≤100 mmHg, and the number of diastolic blood pressure of ≥90mmHg or ≤60mmHg

          -  A subject who shows the following result in clinical laboratory test:

               -  AST,ALT&gt;1.25 times of the upper limit of normal range

               -  QTc&gt;430msec

               -  T.bil&gt;1.25 times of the upper limit of normal range

          -  A subject from whom over 400mL of blood was sampled(whole blood or plasma donation,
             etc.) within last 8 weeks

          -  Subject who has taken other clinical or licensed medication from another clinical
             trial within an 8-week period prior to the first administration of the study
             medication (The last administration of the medication is considered as an end point of
             the previous clinical trial).

          -  Subject who smokes an average of 10 cigarettes/day and is unable to quit smoking
             during the clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>February 23, 2014</last_update_submitted>
  <last_update_submitted_qc>February 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

